^
Association details:
| Biomarker: | MME negative |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PHASE 2 STUDY OF IBRUTINIB WITH TEMOZOLOMIDE, ETOPOSIDE, LIPOSOMAL DOXORUBICIN, DEXAMETHASONE, RITUXIMAB (TEDDI-R) FOR SECONDARY CNS LYMPHOMA
Published date:
06/09/2023
Excerpt:
88% of ibrutinib-responsive tumors were CD10 neg. Pts with CD10 neg tumors had an ORR of 83%, and a 70% rate of CR. The 1-year PFS and OS for pts with CD10 neg tumors was 48.0% and 64.7%....Ibrutinib-responsive tumors are mostly CD10 negative and TEDDi-R may improve the outcomes of this subgroup.
DOI:
10.1002/hon.3163_17
Trial ID:
